drugset / Trial / NCT06144671

GT201 Injection For The Treatment Of Advanced Solid Tumors

NCT06144671 ↗

Phase 1/2 Recruiting 18 enrolled Grit Biotechnology
NaSequentialOpen-labelTreatment

Summary

Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors),3 dose groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated dose escalation and traditional "3+3" dose escalation.The first dose group is accelerated titration,The first dose group is an accelerated titration of 1 to 6 evaluable subjects;The second and third dose groups are based on the traditional "3+3" dose-escalation principle,The second and third dose groups are based on the traditional "3+3" dose-escalation principle, with 3 to 6 evaluable subjects enrolled respectively.

Timeline

Start
2023-09-13
Primary completion
2026-09-13
Completion
2026-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject GT201 Cell therapy 5e+09 cells —
Subject GT201 Cell therapy 1e+10 cells —
Subject GT201 Cell therapy 5e+10 cells —

Indications